Welcome to

KaNDy
Therapeutics

Developing a breakthrough non-hormonal treatment for multiple symptoms of the menopause including hot flashes and night time awakening

FIND OUT MORE

A unique approach

Progressing our unique once daily dual mechanism neurokinin antagonist, NT-814, as a potential breakthrough treatment for multiple symptoms of the menopause. NT-814 has successfully completed a Phase 2a proof of concept study that demonstrated its potential to rapidly and profoundly reduce two key symptoms of the menopause: hot flashes and night time awakening. Preparations are underway for a multi-country Phase 2b study with NT-814 in this anchor Women’s Health indication, starting in Q4 2018.

Latest News

By
In News
Posted

KaNDy Therapeutics successfully raises £25 million in a Series C financing. Funding to advance a breakthrough non-hormonal treatment for symptoms of the menopause, into a Phase 2b study in Q4 2018

Stevenage, UK, 29 August 2018 – KaNDy Therapeutics, a clinical-stage Women’s Health company, today announces it has successfully closed a [...]

READ MORE

Contact Us

For general, media or partnership enquiries, get in touch with us:

Contact Us
Contact Us

Please fill out the form to get in touch with us.

Not readable? Change text. captcha txt